Dose: 1.428 to 2.857 mg/kg
Single Dose: 2.1 (2.1425)
Frequency: As recommended.
Route: PO
Instructions: At bed time

Dose: Should not be used in children
Single Dose:
Frequency:
Route:
Instructions:

Dose: Should not be used in children
Single Dose:
Frequency:
Route:
Instructions:

Pentobarbitone (Na) also known as Pentobarbital. . It is of Natural origin and belongs to Barbiturate. It belongs to Chloride Channel opener (Gaba operated) pharmacological group on the basis of mechanism of action and also classified in Sedatives and Hypnotics pharmacological group.The Molecular Weight of Pentobarbitone (Na) is 248.30. It is weakly alkaline drug, 4.07% solution of the drug is isotonic and Its pKa is 8.1.

Pentobarbitone (Na) is contraindicated in conditions like Pain,Pulmonary insufficiency,Porphyria,Sleep apnea syndrome.

The severe or irreversible adverse effects of Pentobarbitone (Na), which give rise to further complications include Ataxia, Fever, Angioneurotic edema, Skin reactions, Sedation, Megaloblastic anemia, Myalgia, Neuralgia, Arthritic pain, Slurred speech.Pentobarbitone (Na) produces potentially life-threatening effects which include Carcinogenicity, Impaired conciousness. which are responsible for the discontinuation of Pentobarbitone (Na) therapy.The signs and symptoms that are produced after the acute overdosage of Pentobarbitone (Na) include Bradycardia, Hypotension, Coma, Respiratory depression, Hypothermia, Miosis, Renal failure, Oliguria, Shock, CNS depression, Hyper-reflexia, Cardiac depression, Pupillary constriction.The symptomatic adverse reactions produced by Pentobarbitone (Na) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Drowsiness, Excitement, Nausea, Confusion, VertigoX, Sedation, Photosensitivity, Unsteadiness, Loss of memory.

Pentobarbitone (Na) is primarily indicated in conditions like Insomnia, and can also be given in adjunctive therapy as an alternative drug of choice in Raised intracranial pressure.

Pentobarbitone (Na) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholCaffeineHydrocortisoneMephenesinMetoprolol (Tartrate)QuinidineWarfarin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Cap, Elixir, Inj Store at room temperature, Below 30°C. Do not Freeze. Protect from Heat. Suppositories Store in refrigerator.

Pentobarbitone should not be used in patients with bronchopneumonia or status asthmaticus because it could increase respiratory depression. The drug should be used cautiously in patients with major depression or suicidal ideation, because the CNS-depressant effects of the drug can exacerbate the condition. Because of reduced renal or hepatic function, geriatric patients may require reduced doses. Pentobarbital should be used cautiously in patients with uncontrolled acute or chronic pain, with renal and the hepatic disease. It should be used with caution in patients who must perform hazardous tasks because depression of the CNS can produce effects of drowsiness and loss of mental alertness.Pentobarbitone, administered parenterally, should be used with caution in cases of hypotension, pulmonary disease, or cardiovascular disease because of possible adverse hemodynamic effects. IV administration can cause respiratory depression and should be administered slowly to avoid hypotension. It should not be prescribed in high doses for prolonged use because of the potential for psychological and physical dependence. It should not recommended for use during pregnancy because fetal abnormalities have been reported. Use of pentobarbitone in the third trimester can result in physical dependence in the neonate. If used during labor, neonates should be carefully observed for signs of respiratory depression. Premature babies are particularly sensitive to respiratory depression. Caution should be done in administering these drugs to patients with skin disease who may be predisposed to allergic reactions. Pentobarbitone is excreted into breast milk and can cause CNS depression in infants of breast-feeding mothers.Tolerance and physiological dependence can occur with pentobarbitone. Abrupt discontinuation of prolonged barbiturate therapy can result in withdrawal symptoms.